LAVAL, Quebec, Oct. 30, 2018 /CNW/ -- Bausch Health
Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company")
today announced its board of directors has elected Dr. Andrew C. von Eschenbach to serve as a director,
effective Oct. 29, 2018. With the
addition of Dr. von Eschenbach, Bausch Health has a total of 11
members on its board, 10 of whom are independent.
"I am pleased to welcome Dr. Andrew von
Eschenbach to the Bausch Health board of directors," said
Joseph C. Papa, chairman and CEO,
Bausch Health. "Andy's multiple
roles throughout his distinguished career, ranging from his service
as commissioner of the U.S. Food and Drug Administration and as
director of the National Cancer Institute to his more than 25 years
at the University of Texas MD Anderson
Cancer Center, make him an invaluable addition to the board."
Dr. von Eschenbach was appointed acting commissioner of the U.S.
Food and Drug Administration in 2005, was later confirmed by the
Senate as commissioner in 2006 and then held the role until his
resignation in 2009. Prior to that, he served as director of the
National Cancer Institute at the National Institutes of Health from
2002 to 2006. Dr. von Eschenbach also previously served as a
physician, surgeon, oncologist and executive at the University of Texas MD Anderson Cancer Center from
1976 until 2002, and since 2009, he has continued to serve as an
adjunct professor there. He also currently serves as president of
Samaritan Health Initiative and as a senior fellow at the Milken
Institute.
In 2006, Dr. von Eschenbach was named to the "Time 100," the
magazine's annual list of the 100 most influential people to shape
the world. Additionally, he was selected in both 2007 and 2008 as
one of the Modern Healthcare/Modern Physician's "50 Most Powerful
Physician Executives in Healthcare."
Dr. von Eschenbach earned a B.S. from St. Joseph's University and a M.D. from
Georgetown University. Following
medical school, he served as a lieutenant commander in the U.S.
Naval Medical Corps. He completed his residency at Pennsylvania
Hospital in Philadelphia and
served as an instructor in Urology at the University of Pennsylvania School of Medicine. He
then completed a fellowship in Urologic Oncology at the
University of Texas MD Anderson Cancer
Center.
"Bausch Health is working to build a company focused on
developing and delivering innovative medicines and treatments that
help meet significant unmet medical needs of patients around the
world," said Dr. von Eschenbach. "I look forward to helping guide
the company in its transformation."
About Bausch Health
Bausch Health Companies Inc.
(NYSE/TSX: BHC) is a global company whose mission is to improve
people's lives with our health care products. We develop,
manufacture and market a range of pharmaceutical, medical device
and over-the-counter products, primarily in the therapeutic areas
of eye health, gastroenterology and dermatology. We are delivering
on our commitments as we build an innovative company dedicated to
advancing global health. More information can be found at
www.bauschhealth.com.
Forward-looking Statements
This news release may
contain forward-looking statements, which may generally be
identified by the use of the words "anticipates," "is working to
build", "expects," "intends," "plans," "should," "could," "would,"
"may," "will," "believes," "estimates," "potential," "target," or
"continue" and variations or similar expressions. These statements
are based upon the current expectations and beliefs of management
and are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include,
but are not limited to, risks and uncertainties discussed in the
Company's most recent annual or quarterly report and detailed from
time to time in the Company's other filings with the Securities and
Exchange Commission and the Canadian Securities Administrators,
which factors are incorporated herein by reference. In addition,
certain material factors and assumptions have been applied in
making these forward-looking statements, including that the risks
and uncertainties outlined above will not cause actual results or
events to differ materially from those described in these
forward-looking statements. The Company believes that the material
factors and assumptions reflected in these forward-looking
statements are reasonable, but readers are cautioned not to place
undue reliance on any of these forward-looking statements. These
forward-looking statements speak only as of the date hereof. Bausch
Health undertakes no obligation to update any of these
forward-looking statements to reflect events or circumstances after
the date of this news release or to reflect actual outcomes, unless
required by law.
Investor
Contact:
|
Media
Contact:
|
Arthur
Shannon
|
Lainie
Keller
|
arthur.shannon@bauschhealth.com
|
lainie.keller@bauschhealth.com
|
(514)
856-3855
|
(908)
927-0617
|
(877) 281-6642 (toll
free)
|
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/dr-andrew-c-von-eschenbach-joins-bausch-health-board-of-directors-300739855.html
SOURCE Bausch Health Companies Inc.